company background image
PSTX

Poseida Therapeutics NasdaqGS:PSTX Stock Report

Last Price

US$2.18

Market Cap

US$136.7m

7D

3.3%

1Y

-75.3%

Updated

16 May, 2022

Data

Company Financials +
PSTX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

PSTX Stock Overview

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs.

Poseida Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Poseida Therapeutics
Historical stock prices
Current Share PriceUS$2.18
52 Week HighUS$11.10
52 Week LowUS$1.83
Beta0
1 Month Change-46.44%
3 Month Change-45.77%
1 Year Change-75.34%
3 Year Changen/a
5 Year Changen/a
Change since IPO-85.80%

Recent News & Updates

May 15
Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

It's been a sad week for Poseida Therapeutics, Inc. ( NASDAQ:PSTX ), who've watched their investment drop 12% to...

Shareholder Returns

PSTXUS BiotechsUS Market
7D3.3%4.8%0.7%
1Y-75.3%-22.0%-10.8%

Return vs Industry: PSTX underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: PSTX underperformed the US Market which returned -10.4% over the past year.

Price Volatility

Is PSTX's price volatile compared to industry and market?
PSTX volatility
PSTX Average Weekly Movement13.9%
Biotechs Industry Average Movement12.3%
Market Average Movement7.8%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market2.9%

Stable Share Price: PSTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: PSTX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2014283Mark Gergenhttps://www.poseida.com

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers.

Poseida Therapeutics Fundamentals Summary

How do Poseida Therapeutics's earnings and revenue compare to its market cap?
PSTX fundamental statistics
Market CapUS$136.70m
Earnings (TTM)-US$144.72m
Revenue (TTM)US$32.67m

4.2x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PSTX income statement (TTM)
RevenueUS$32.67m
Cost of RevenueUS$19.76m
Gross ProfitUS$12.92m
Other ExpensesUS$157.64m
Earnings-US$144.72m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.31
Gross Margin39.54%
Net Profit Margin-442.92%
Debt/Equity Ratio55.9%

How did PSTX perform over the long term?

See historical performance and comparison

Valuation

Is Poseida Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


1.32x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PSTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PSTX's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: PSTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: PSTX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PSTX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PSTX is good value based on its PB Ratio (1.3x) compared to the US Biotechs industry average (1.4x).


Future Growth

How is Poseida Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-8.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PSTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PSTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PSTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PSTX's revenue (5.2% per year) is forecast to grow slower than the US market (8% per year).

High Growth Revenue: PSTX's revenue (5.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PSTX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Poseida Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-32.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PSTX is currently unprofitable.

Growing Profit Margin: PSTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PSTX is unprofitable, and losses have increased over the past 5 years at a rate of 32.9% per year.

Accelerating Growth: Unable to compare PSTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PSTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: PSTX has a negative Return on Equity (-139.55%), as it is currently unprofitable.


Financial Health

How is Poseida Therapeutics's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PSTX's short term assets ($190.5M) exceed its short term liabilities ($43.9M).

Long Term Liabilities: PSTX's short term assets ($190.5M) exceed its long term liabilities ($100.5M).


Debt to Equity History and Analysis

Debt Level: PSTX has more cash than its total debt.

Reducing Debt: PSTX's debt to equity ratio has increased from 16.6% to 55.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PSTX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PSTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31.4% each year


Dividend

What is Poseida Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PSTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PSTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PSTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PSTX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PSTX has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Mark Gergen (58 yo)

0.25

Tenure

US$2,823,916

Compensation

Mr. Mark J. Gergen, J.D., has been Chief Executive Officer at Poseida Therapeutics, Inc. since February 01, 2022 and serves as its Director and served as Chief Business Officer of Poseida Therapeutics, Inc...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD2.82M) is above average for companies of similar size in the US market ($USD770.21K).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PSTX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: PSTX's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PSTX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Poseida Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Poseida Therapeutics, Inc.
  • Ticker: PSTX
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$136.696m
  • Shares outstanding: 62.70m
  • Website: https://www.poseida.com

Number of Employees


Location

  • Poseida Therapeutics, Inc.
  • 9390 Towne Centre Drive
  • Suite 200
  • San Diego
  • California
  • 92121
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/16 00:00
End of Day Share Price2022/05/16 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.